Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts remain broadly bullish: Halozyme has a “Moderate Buy” consensus from 13 analysts, with nine Buy, three Hold and one Sell rating. The average 12-month price target is $91.20, below the stock’s recent $110.19 price.
• Quarterly results exceeded expectations: The company reported $2.28 in EPS versus the $1.79 consensus estimate, while revenue rose 47.7% year over year to $481 million. Management issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Momentum and institutional support are strong: HALO recently traded near its 52-week high, and institutional investors own 97.79% of shares. However, insiders have sold 32,478 shares worth approximately $3.1 million over the past 90 days.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $91.20.

Several analysts recently issued reports on HALO shares. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a report on Friday, August 7th. HC Wainwright reissued a "buy" rating and set a $115.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a report on Tuesday, May 12th. Weiss Ratings raised Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday. Finally, Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analyst maintains Buy rating: HC Wainwright reaffirmed its Buy rating on Halozyme Therapeutics, supporting the bullish view of the company’s growth outlook. HC Wainwright Reaffirms Buy Rating for Halozyme Therapeutics
• Positive Sentiment: Higher earnings expectations: Zacks Research raised its FY2026 EPS forecast to $8.24 from $7.56, above the provided consensus estimate of $7.98. It also lifted forecasts for several 2027 and 2028 quarters, including FY2027 EPS to $9.01 from $8.96, indicating improving expectations for Halozyme’s earnings trajectory. Zacks Research Issues Positive Forecast for HALO Earnings
• Positive Sentiment: Value and growth appeal: Zacks included HALO among four high-growth stocks with discounted PEG ratios for 2026. The designation may attract investors seeking earnings growth at a relatively reasonable valuation, particularly after Halozyme’s strong recent results and revenue growth. 4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
• Neutral Sentiment: Momentum has been strong: HALO recently hit a new one-year high, reflecting investor enthusiasm and continued upward momentum. However, trading near that high can also increase sensitivity to profit-taking and valuation concerns. Halozyme Therapeutics Hits New 1-Year High
• Negative Sentiment: One longer-term estimate was trimmed: Zacks lowered its FY2028 EPS forecast to $10.06 from $10.21, a minor reduction that partially offsets the otherwise positive revisions.

Halozyme Therapeutics Stock Performance

HALO opened at $110.19 on Friday. The company has a market cap of $12.51 billion, a PE ratio of 32.89, a price-to-earnings-growth ratio of 0.43 and a beta of 0.88. The stock has a 50-day moving average of $90.76 and a 200-day moving average of $75.82. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $111.15. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same quarter in the prior year, the firm posted $1.54 EPS. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics will post 7.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director owned 14,462 shares of the company's stock, valued at $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares of the company's stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,478 shares of company stock valued at $3,076,604 in the last 90 days. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. California State Teachers Retirement System raised its position in shares of Halozyme Therapeutics by 7,724.2% during the second quarter. California State Teachers Retirement System now owns 10,668,044 shares of the biopharmaceutical company's stock valued at $834,988,000 after buying an additional 10,531,698 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company's stock valued at $241,337,000 after buying an additional 749,484 shares during the period. Bank of America Corp DE acquired a new stake in Halozyme Therapeutics during the second quarter worth about $214,504,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics during the second quarter worth about $196,540,000. Finally, Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company's stock valued at $141,613,000 after acquiring an additional 25,731 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source